Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption

por Terciolo, Chloe, Dapoigny, Michel, Andre, Frederic
Publicado 2019

Assessment of the effectiveness and safety of ethosuximide in the treatment of abdominal pain related to irritable bowel syndrome – IBSET: protocol of a randomised, parallel, contr...

por Kerckhove, Nicolas, Scanzi, Julien, Pereira, Bruno, Ardid, Denis, Dapoigny, Michel
Publicado 2017

Prokaryotic and Eukaryotic Fecal Microbiota in Irritable Bowel Syndrome Patients and Healthy Individuals Colonized With Blastocystis

por Nourrisson, Céline, Scanzi, Julien, Brunet, Julie, Delbac, Frédéric, Dapoigny, Michel, Poirier, Philippe
Publicado 2021

The human intestinal microbiota of constipated-predominant irritable bowel syndrome patients exhibits anti-inflammatory properties

por Gobert, Alain P., Sagrestani, Giulia, Delmas, Eve, Wilson, Keith T., Verriere, Thomas G., Dapoigny, Michel, Del’homme, Christophe, Bernalier-Donadille, Annick
Publicado 2016

Blastocystis Is Associated with Decrease of Fecal Microbiota Protective Bacteria: Comparative Analysis between Patients with Irritable Bowel Syndrome and Control Subjects

por Nourrisson, Céline, Scanzi, Julien, Pereira, Bruno, NkoudMongo, Christina, Wawrzyniak, Ivan, Cian, Amandine, Viscogliosi, Eric, Livrelli, Valérie, Delbac, Frédéric, Dapoigny, Michel, Poirier, Philippe
Publicado 2014